Delaware court backs UCB drug patent, shares jump

(Reuters) - A ruling by the Delaware District Court in the United States upholding the validity of UCB's patent for epilepsy drug Vimpat sent shares in the Belgian pharmaceutical firm up more than 7 percent on Monday.Sales of the drug totaled 679 million euros ($759 million) last year, of which about three quarters were in the United States.(Reporting by Wout Vergauwen; editing by Jason Neely)Join the conversation about this story
Click here to read full news..